{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "INT-7",
        "affectedSection": "Section 1.6, 1.7 - Clinical Safety",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated safety information to include cerebrovascular accidents as a new safety observation from post-marketing settings."
      },
      {
        "id": "impact_2",
        "amendmentId": "INT-7",
        "affectedSection": "Table 1, Section 9.5 - Safety Evaluations",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added mandatory pulse/heart rate and blood pressure monitoring at every protocol-specified visit."
      },
      {
        "id": "impact_3",
        "amendmentId": "INT-5",
        "affectedSection": "Section 6.4.3.1 - Dose Modification",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added specific dose modification instructions for subjects with chronic hepatic impairment based on Child-Pugh classification."
      },
      {
        "id": "impact_4",
        "amendmentId": "INT-2",
        "affectedSection": "Section 12.3.3.1 - Major Hemorrhage",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Broadened the definition of major hemorrhagic events to include any Grade 3+ event or CNS hemorrhage."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "INT-7",
        "reasonText": "To update safety information to align with the ibrutinib Investigatorâ€™s Brochure (IB) regarding cerebrovascular accidents.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "INT-6",
        "reasonText": "To halt the collection of complete response (CR) minimal residual disease (MRD) samples for subjects already having an MRD-negative sample.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "INT-4",
        "reasonText": "Addition of a second interim analysis to mitigate for the potential long interval between the first interim and final analysis.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "INT-7",
        "reasonText": "Minor editorial changes implemented to correct typographical errors and address inconsistencies.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "INT-2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "12.3.3.1",
        "beforeText": "Any hemorrhagic event that is Grade 3 or greater in severity or that results in 1 of the following: intraocular bleeding causing loss of vision, the need for a transfusion of 2 or more units of red cells...",
        "afterText": "Any treatment-emergent hemorrhagic adverse event of Grade 3 or higher; Any treatment-emergent serious adverse event of bleeding; Any CNS hemorrhage/hematoma of any grade.",
        "summary": "Broadened scope of major hemorrhage definition."
      },
      {
        "id": "change_2",
        "amendmentId": "INT-2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1",
        "beforeText": "Hematology values must be within the following limits within 14 days prior to randomization",
        "afterText": "Hematology values must be within the following limits:",
        "summary": "Removed the specific 14-day timeframe for laboratory parameter eligibility."
      },
      {
        "id": "change_3",
        "amendmentId": "INT-2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.3",
        "beforeText": "Not specified",
        "afterText": "If a dose of study drug is not taken at the scheduled time, it can be taken as soon as possible on the same day with a return to the normal schedule the following day.",
        "summary": "Updated missed dose instructions for consistency with product label."
      },
      {
        "id": "change_4",
        "amendmentId": "INT-3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.2.2.3",
        "beforeText": "1.1 cm",
        "afterText": "1.0 cm",
        "summary": "Corrected the short axis measurement for previously involved nodes in CR criteria."
      },
      {
        "id": "change_5",
        "amendmentId": "INT-7",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "Table 1",
        "beforeText": "Standard vital signs",
        "afterText": "Footnote j added: vital sign assessments should be recorded in source documents but will not be routinely collected in the eCRF.",
        "summary": "Clarified recording requirements for pulse and blood pressure monitoring."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}